Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Status Epilepticus
Am J Med 69:657-665, Aminoff,M.J.,et al, 1980
Is Prophylactic Anticoagulation for Deep Venous Thrombosis Common Practice after Intracerebral Hemorrhage?
Stroke 46:369-375, Prabhakaran, S.,et al, 2015
Pilot Randomized Trial of Outpatient Cardiac Monitoring After Cryptogenic Stroke
Stroke 44:528-530, Kamel, H.,et al, 2013
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Increased Risk of Stroke After Discontinuation of Acetlysalicylic Acid: A UK Primary Care Study
Neurol 76:740-746, Rodr�guez,L.A.G.,et al, 2011
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Impact of a Better Adherence to Antihypertensive Agents on Cerebrovascular Disease for Primary Prevention
Stroke 40:213-220, Kettani,F.-Z.,et al, 2009
Nonadherence to Antiepileptic Drugs and Increased Mortality: Findings from the RANsom Study
Neurol 71:1572-1578, Faught,E.,et al, 2008
Compliance With Secondary Prevention of Ischemic Stroke
Stroke 32:1884-1889, Sappok,T.,et al, 2001